UK doctors look back at real-world use of new VWD drug

NCT ID NCT06433778

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looked back at medical records of 34 adults with von Willebrand disease (VWD) in the UK who received a newer treatment called vonicog alfa (rVWF). The goal was to see how well it controlled bleeding and was used during surgeries in real-world settings. No new treatments or tests were given; researchers simply collected existing data from routine care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Imperial College Healthcare

    London, W2 1NY, United Kingdom

  • Leeds Teaching Hospital

    Leeds, LS9 7TF, United Kingdom

  • Liverpool University Hospital

    Liverpool, L7 8XP, United Kingdom

  • Manchester University

    Manchester, M13 9WL, United Kingdom

  • Oxford University Hospital

    Oxford, OX3 9DU, United Kingdom

  • Royal Free London

    London, NW3 2QG, United Kingdom

  • University Hospitals Birmingham

    Birmingham, B15 2GW, United Kingdom